denovoSkin™
Severe Burns & Reconstructive Surgery
Phase 2Active
Key Facts
About Cutiss
CUTISS is a pioneering Swiss biotech company developing denovoSkin™, a personalized, bioengineered skin graft intended to replace the current standard of autografting. The company operates a state-of-the-art GMP facility and has developed a proprietary, automated manufacturing platform for scalable production. With denovoSkin™ in late-stage clinical trials and holding Orphan Drug Designations from major regulatory bodies, CUTISS is positioned to address significant unmet needs in burn care, reconstructive surgery, and beyond, while also exploring applications in regenerative medicine and space health research.
View full company profile